DeepMed Research

Hangzhou Zhongmei Huadong Pharmaceutical Co.,Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Single dose of HDM1002 on Day 1

First Posted Date: 2025-05-22

Last Posted Date: 2025-05-22

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06985615

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: HDM1005 injection or placebo

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06886126

Locations: 🇨🇳
The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Phase 3

Not yet recruiting

Conditions: Overweight and Obesity

Interventions: Drug: HDM1002 200mg, oral, once daily, 52 weeks
Drug: HDM1002 400mg, oral, once daily, 52 weeks
Drug: HDM1002 placebo, oral, once daily, 52 weeks

First Posted Date: 2025-03-19

Last Posted Date: 2025-03-19

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 780

Registration Number: NCT06885021

Efficacy and Safety of Semaglutide Injection Vs Ozempic® in Patients with Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Ozempic®
Drug: HDG1901

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 494

Registration Number: NCT06739044

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Roflumilast Cream 0.3%
Drug: Vehicle cream

First Posted Date: 2024-10-18

Last Posted Date: 2025-05-16

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 189

Registration Number: NCT06648772

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
The Second People's Hospital of Chengdu, Chengdu, China
🇨🇳
The Sixth People's Hospital of Dongguan, Dongguan, China

and more 28 locations

Phase Ia Clinical Study of HDM1005 Injection

Phase 1

Completed

Conditions: Obesity and Overweight

Interventions: Drug: HDM1005 injection or placebo

First Posted Date: 2024-10-14

Last Posted Date: 2024-10-14

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT06640647

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Phase Ib Clinical Study of HDM1005 Injection

Phase 1

Recruiting

Conditions: Overweight and Obesity

Interventions: Drug: HDM1005 injection or placebo

First Posted Date: 2024-10-11

Last Posted Date: 2024-10-11

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT06637020

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

Phase 1

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: HDG1901
Drug: Ozempic®

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-10

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 68

Registration Number: NCT06634927

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis

Phase 3

Recruiting

Conditions: Atopic Dermatitis (AD)

Interventions: Drug: Roflumilast Cream 0.15%
Drug: Vehicle cream

First Posted Date: 2024-10-08

Last Posted Date: 2025-02-20

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 351

Registration Number: NCT06631170

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Medical University Affiliated Second Hospital, Chongqing, Chongqing, China
🇨🇳
People's Hospital Affiliated to Chongqing Three Gorges Medical College, Chongqing, Chongqing, China

and more 58 locations

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Advanced Solid Tumors
Refractory Lymphoma
Relapsed Hematologic Malignancy

Interventions: Drug: HDM2005

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 111

Registration Number: NCT06615193

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy